Precision Oncology: a Clinical and Patient Perspective

References

• Chae YK , PanAP, DavisAAet al. Path toward precision oncology: review of targeted therapy studies and tools to aid in defining ‘actionability’ of a molecular lesion and patient management support. Mol. Cancer Ther.16(12), 2645–2655 (2017).
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration . Drug approvals and databases. www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
   Google Scholar
• European Medicines Agency . Medicines. www.ema.europa.eu/en/medicines
   Google Scholar
• Sabir SR , YeohS, JacksonG, BaylissR. EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers9(9), 118 (2017).
   PubMed Web of Science ®Google Scholar
• Riely GJ , YuHA. EGFR: the paradigm of an oncogene-driven lung cancer. Clin. Cancer Res.21(10), 2221–2226 (2015).
   PubMed Web of Science ®Google Scholar
• Chae YK , RanganathK, HammermanPSet al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget8(9), 16052–16074 (2017).
   PubMedGoogle Scholar
• Zhou Y , WuC, LuG, HuZ, ChenQ, DuX. FGF/FGFR signaling pathway involved resistance in various cancer types. J. Cancer.11(8), 2000–2007 (2020).
   PubMed Web of Science ®Google Scholar
• Li AY , McCuskerMG, RussoAet al. RET fusions in solid tumors. Cancer Treat. Rev.81, 101911 (2019).
   PubMed Web of Science ®Google Scholar
• Subbiah V , CoteGJ. Advances in targeting RET-dependent cancers. Cancer Discov.10(4), 498–505 (2020).
   PubMed Web of Science ®Google Scholar
• Giustini NP , BazhenovaL. ROS1-rearranged non-small cell lung cancer. Thorac. Surg. Clin.30(2), 147–156 (2020).
   PubMed Web of Science ®Google Scholar
• Patil T , SimonsE, MushtaqR, PachecoJM, DoebeleRC, BowlesDW. Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs Today55(10), 641–652 (2019).
   PubMed Web of Science ®Google Scholar
• Yang J , NieJ, MaX, WeiY, PengY, WeiX. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol. Cancer18(1), 26 (2019).
   PubMed Web of Science ®Google Scholar
• Croce L , CoperchiniF, MagriF, ChiovatoL, RotondiM. The multifaceted anti-cancer effects of BRAF-inhibitors. Oncotarget10(61), 6623–6640 (2019).
   PubMedGoogle Scholar
• Kelly CM , GutierrezSainz L, ChiP. The management of metastatic GIST: current standard and investigational therapeutics. J. Hematol. Oncol.14(1), 2 (2021).
   PubMed Web of Science ®Google Scholar
• File D , CuriglianoG, CareyLA. Escalating and de-escalating therapy for early-stage HER2-positive breast cancer. Am. Soc. Clin. Oncol. Educ. Book40, 1–11 (2020).
   PubMedGoogle Scholar
• Jang A , SartorO, BarataPC, PallerCJ. Therapeutic potential of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer. Cancers12(11), 3467 (2020).
   PubMed Web of Science ®Google Scholar
• Li K , LuoH, HuangL, LuoH, ZhuX. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int.20, 16 (2020).
   PubMed Web of Science ®Google Scholar
• Amatu A , Sartore-BianchiA, BencardinoK, PizzutiloEG, TosiF, SienaS. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann. Oncol.30(Suppl. 8), VIII5–VIII15 (2019).
   PubMedGoogle Scholar
• Marino FZ , PagliucaF, RonchiAet al. NTRK fusions, from the diagnostic algorithm to innovative treatment in the era of precision medicine. Int. J. Mol. Sci.21(10), 1–15 (2020).
   Web of Science ®Google Scholar
• Shao C , LiG, HuangLet al. Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. JAMA Netw. Open.3(10), e2025109 (2020).
   PubMed Web of Science ®Google Scholar
• Xie J , LuX, WuXet al. Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing. Mol. Genet. Genom. Med.4(3), 262–272 (2016).
   PubMed Web of Science ®Google Scholar
• Hillman RT , WardK, SaenzC, McHaleM, PlaxeS. Barriers prevent patient access to personalized therapies identified by molecular tumor profiling of gynecologic malignancies. J. Pers. Med.5(2), 165–173 (2015).
   PubMedGoogle Scholar
• Arsenic R , TreueD, LehmannAet al. Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. BMC Clin. Pathol.15, 20 (2015).
   PubMed Web of Science ®Google Scholar
• Hux A , LewisA, SachwitzD, GregoryT. Clinical utility of next-generation sequencing in precision oncology. J. Am. Acad. Phys. Assist.32(1), 35–39 (2019).
   Google Scholar
• Meldi K , QinT, BuchiFet al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J. Clin. Invest.125(5), 1857–1872 (2015).
   PubMed Web of Science ®Google Scholar
• Walker BA , BoyleEM, WardellCPet al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol.33(33), 3911–3920 (2015).
   PubMed Web of Science ®Google Scholar
• Sato Y , MatobaR, KatoK. Recent advances in liquid biopsy in precision oncology research. Biol. Pharm. Bull.42(3), 337–342 (2019).
   PubMed Web of Science ®Google Scholar
• Pfaff E , de BeaumaisT, MarchaisAet al. NTRK alterations in pediatric relapsed/refractory/very high risk malignancies identified through European clinical sequencing programs constitute promising drug targets. J. Clin. Oncol. Prec. Oncol.5, 450–454 (2021).
   PubMed Web of Science ®Google Scholar
• Brown NA , Elenitoba-JohnsonKSJ. Enabling precision oncology through precision diagnostics. Annu. Rev. Pathol.15, 97–121 (2020).
   PubMed Web of Science ®Google Scholar
• Galuppini F , DalPozzo CA, DeckertJ, LoupakisF, FassanM, BaffaR. Tumor mutation burden: from comprehensive mutational screening to the clinic. Cancer Cell Intern.19, 209 (2019).
   PubMed Web of Science ®Google Scholar
• Tan O , ShresthaR, CunichM, SchofieldDJ. Application of next-generation sequencing to improve cancer management: a review of the clinical effectiveness and cost-effectiveness. Clin. Genet.93(3), 533–544 (2018).
   PubMed Web of Science ®Google Scholar
• Ascierto PA , KirkwoodJM, GrobJ-Jet al. The role of BRAF V600 mutation in melanoma. J. Transl. Med.10, 85 (2012).
   PubMed Web of Science ®Google Scholar
• Planchard D , SmitEF, GroenHJMet al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, Phase 2 trial. Lancet Oncol.18(10), 1307–1316 (2017).
   PubMed Web of Science ®Google Scholar
• Long GV , StroyakovskiyD, GogasHet al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, Phase 3 randomised controlled trial. Lancet386(9992), 444–451 (2015).
   PubMed Web of Science ®Google Scholar
• Subbiah V , KreitmanRJ, WainbergZAet al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J. Clin. Oncol.36(1), 7–13 (2018).
   PubMed Web of Science ®Google Scholar
• Subbiah V , LassenU, ÉlezEet al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a Phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol.21(9), 1234–1243 (2020).
   PubMed Web of Science ®Google Scholar
• Yang H , HigginsB, KolinskyKet al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res.72(3), 779–789 (2012).
   PubMed Web of Science ®Google Scholar
• van Geel RMJM , TaberneroJ, ElezEet al. A Phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov.7(6), 610–619 (2017).
   PubMed Web of Science ®Google Scholar
• Mao M , TianF, MariadasonJMet al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin. Cancer Res.19(3), 657–667 (2013).
   PubMed Web of Science ®Google Scholar
• Alshareef A . Novel molecular challenges in targeting anaplastic lymphoma kinase in ALK-expressing human cancers. Cancers9(11), 1–13 (2017).
   Web of Science ®Google Scholar
• Brown NA , Elenitoba-JohnsonKSJ. Enabling precision oncology through precision diagnostics. Annu. Rev. Pathol. Mech. Dis.15(1), 97–121 (2020).
   PubMedGoogle Scholar
• Kurnit K , DumbravaE, LitzenburgerBet al. Precision oncology decision support: current approaches and strategies for the future. Clin. Cancer Res.24(12), 2719–2731 (2018).
   PubMed Web of Science ®Google Scholar
• Khan T , StewartM, BlackmanSet al. Accelerating pediatric cancer drug development: challenges and opportunities for pediatric master protocols. Ther. Innov. Regul. Sci.53(2), 270–278 (2019).
   PubMed Web of Science ®Google Scholar
• Beltran H , EngK, MosqueraJMet al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol.1(4), 466–474 (2015).
   PubMed Web of Science ®Google Scholar
• Kato S , KimKH, LimHJet al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-one strategy. Nat. Commun.11(1), 4965 (2020).
   PubMed Web of Science ®Google Scholar
• Massard C , MichielsS, FertéCet al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov.7(6), 586–595 (2017).
   PubMed Web of Science ®Google Scholar
• Tuxen IV , RohrbergKS, OestrupOet al. Copenhagen Prospective Personalized Oncology (CoPPO) – clinical utility of using molecular profiling to select patients to Phase I trials. Clin. Cancer Res.25(4), 1239–1247 (2019).
   PubMed Web of Science ®Google Scholar
• Zehir A , BenayedR, ShahRHet al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10.000 patients. Nat. Med.23(6), 703–713 (2017).
   PubMed Web of Science ®Google Scholar
• Brock A , HuangS. Precision oncology: between vaguely right and precisely wrong. Cancer Res.77(23), 6473–6479 (2017).
   PubMed Web of Science ®Google Scholar
• Sánchez NS , MillsGB, ShawKRM. Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics18(16), 1525–1539 (2017).
   PubMed Web of Science ®Google Scholar
• American Association for Cancer Research . AACR Project GENIE. http://aacr.org/genie
   Google Scholar
• AACR Project GENIE Consortium . AACR Project GENIE: powering precision medicine through an international consortium. Cancer Disc.7(8), 818–831 (2017).
   Web of Science ®Google Scholar
• Syapse Inc . Syapse Learning Health Network (2021). www.syapse.com/offerings/syapse-learning-health-network
   Google Scholar
• Northwestern University . OncoSET Precision Medicine (2021). http://cancer.northwestern.edu/oncoset
   Google Scholar
• Schwaederle M , ParkerBA, SchwabRBet al. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist19(6), 631–636 (2014).
   PubMed Web of Science ®Google Scholar
• Patel M , KatoSM, KurzrockR. Molecular tumor boards: realizing precision oncology therapy. Clin. Pharmacol. Ther.103(2), 206–209 (2018).
   PubMed Web of Science ®Google Scholar
• Li MM , DattoM, DuncavageEJet al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn.19(1), 4–23 (2017).
   PubMed Web of Science ®Google Scholar
• Mateo J , ChakravartyD, DienstmannRet al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol.29(9), 1895–1902 (2018).
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F , JohnsonA, HollaVet al. A decision support framework for genomically informed investigational cancer therapy. J. Natl Cancer Inst.107(7), djv098 (2015).
   PubMedGoogle Scholar
• University of Texas MD Anderson Cancer Center . Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (2021). www.mdanderson.org/research/departments-labs-institutes/institutes/zayed-institute-for-personalized-cancer-therapy.html
   Google Scholar
• IBM Watson Health . IB Watson for Genomics. www.ibm.com/watson/health/oncology/genomics/
   Google Scholar
• Patel NM , MicheliniVV, SnellJMet al. Enhancing next-generation sequencing-guided cancer care through cognitive computing. Oncologist23(2), 179–185 (2018).
   PubMed Web of Science ®Google Scholar
• Barnes TA , AmirE, TempletonAJet al. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat. Rev.56, 1–7 (2017).
   PubMed Web of Science ®Google Scholar
• Schirrmacher V . From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int. J. Oncol.54(2), 407–419 (2019).
   PubMed Web of Science ®Google Scholar
• Haanen JBAG , CarbonnelF, RobertCet al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.28(Suppl. 4), iv119–iv142 (2017).
   PubMedGoogle Scholar
• André T , AmonkarM, NorquistJet al. Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): ph. Ann. Oncol.31(Suppl. 4), S409–S461 (2020).
   Google Scholar
• KEYTRUDA® [package insert]. Merck & Co., Inc, NJ, USA (2020). www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
   Google Scholar
• Marabelle A , LeDT, AsciertoPAet al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J. Clin. Oncol.38(1), 1–10 (2020).
   PubMed Web of Science ®Google Scholar
• André T , ShiuK-K, KimTWet al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med.383(23), 2207–2218 (2020).
   PubMed Web of Science ®Google Scholar
• Marabelle A , FakihM, LopezJet al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, Phase 2 KEYNOTE-158 study. Lancet Oncol.21(10), 1353–1365 (2020).
   PubMed Web of Science ®Google Scholar
• Kummar S , Van TilburgCM, AlbertCMet al. Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population. J. Clin. Oncol.38(Suppl.), Abstract 3614 (2020).
   Google Scholar
• Kummar S , BerlinJ, MascarenhasLet al. Quality of life in adult and pediatric patients with tropomyosin receptor kinase fusion cancer receiving larotrectinib. Curr. Probl. Cancer.doi:10.1016/j.currproblcancer.2021.100734 (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• VITRAKVI Summary of Product Characteristics (SPC). www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf
   Google Scholar
• VITRAKVI® [package insert]. Bayer Healthcare Pharmaceuticals Inc, NJ, USA (2019).
   Google Scholar
• Drilon A , LaetschTW, KummarSet al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med.378(8), 731–739 (2018).
   PubMed Web of Science ®Google Scholar
• Hong DS , DuBoisSG, KummarSet al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three Phase 1/2 clinical trials. Lancet Oncol.21(4), 531–540 (2020).
   PubMed Web of Science ®Google Scholar
• Conley AP , DemetriGD, DoebeleRCet al. Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global Phase II STARTRK-2 study. Ann. Oncol.31(Suppl. 4), S462–S504 (2020).
   Google Scholar
• ROZLYTREK® [package insert]. Genentech USA, Inc, CA, USA (2019). www.gene.com/download/pdf/rozlytrek_prescribing.pdf
   Google Scholar
• Doebele RC , DrilonA, Paz-AresLet al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three Phase 1–2 trials. Lancet Oncol.21(2), 271–282 (2020).
   PubMed Web of Science ®Google Scholar
• Kummar S , MascarenhasL, GeoergerBet al. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. J. Clin. Oncol.37(Suppl. 15), 6602 (2019).
   Web of Science ®Google Scholar
• Gray SW , KimB, ShollLet al. Medical oncologists’ experiences in using genomic testing for lung and colorectal cancer care. J. Oncol. Pract.13(3), e185–e196 (2017).
   PubMed Web of Science ®Google Scholar
• Ciardiello F , AdamsR, TaberneroJet al. Awareness, understanding, and adoption of precision medicine to deliver personalized treatment for patients with cancer: a multinational survey comparison of physicians and patients. Oncologist21(3), 292–300 (2016).
   PubMed Web of Science ®Google Scholar
• Lee MJ , HuenikenK, KuehneNet al. Cancer patient-reported preferences and knowledge for liquid biopsies and blood biomarkers at a comprehensive cancer center. Cancer Manag. Res.12, 1163–1173 (2020).
   PubMed Web of Science ®Google Scholar
• Persaud A , BonhamVL. The role of the health care provider in building trust between patients and precision medicine research programs. Am. J. Bioeth.18(4), 26–28 (2018).
   PubMed Web of Science ®Google Scholar
• Albrecht TA , TaylorAG. Physical activity in patients with advanced-stage cancer: a systematic review of the literature. Clin. J. Oncol. Nurs.16(3), 293–300 (2012).
   PubMed Web of Science ®Google Scholar
• Shilling V , StarkingsR, JenkinsV, FallowfieldL. The pervasive nature of uncertainty – a qualitative study of patients with advanced cancer and their informal caregivers. J. Cancer Surviv.11(5), 590–603 (2017).
   PubMed Web of Science ®Google Scholar